Variable | Number/total number (%); Denominator corresponds to total number of patients for whom data are available |
Age median [interquartile range] | 48 [32–69] |
Male | 40/49 (81.6%) |
Migrant status | 26/49 (53.1%) |
Occupation | |
Employed | 14/48 (29.2%) |
Unemployed | 15/48 (31.3%) |
Retired | 14/48 (29.2%) |
Student | 5/48 (10.4%) |
BCG vaccination | 19/30 (63.3%) |
COPD/Asthma | 8/47 (17.0%) |
Diabetes Mellitus | 8/49 (16.3%) |
HIV infection | 6/48 (12.5%) |
Renal failure | 5/49 (10.2%) |
Liver disease | 7/49 (14.3%) |
Alcohol abusea | 10/49 (20.4%) |
Smokingb | 20/49 (40.8%) |
Drug abuse | 4/47 (8.5%) |
TUBERCULOSIS | |
Previous history of TB | 13/46 (28.3%) |
Site | |
Pulmonary TB only | 36/49 (73.5%) |
Extrapulmonary TB only | 1/49 (2.0%) |
Pulmonary TB/ Extrapulmonary TB(>1 site possible) | 12/49 (24.5%) |
Site of extrapulmonary TB | |
Bone | 2/13 (15.4%) |
Lymphadenitis | 2/13 (15.4%) |
Pleural | 2/13 (15.4%) |
Central Nervous System | 1/13 (7.7%) |
Laryngeal | 1/13 (7.7%) |
Gastrointestinal | 1/13 (7.7%) |
Peritonitis+Lymphadenitis+Pleural+Bone | 1/13 (7.7%) |
Genitourinary+Lymphadenitis | 1/13 (7.7%) |
Central Nervous System+Lymphadenitis | 1/13 (7.7%) |
Bone+Joint+Spondylodiscitis (T5-T11)+Paravertebral abscesses | 1/13 (7.7%) |
Radiological involvement | |
Unilateral cavitary lesions | 10/48 (20.8%) |
Bilateral cavitary lesions | 13/48 (27.1%) |
Bilateral infiltrates (no cavities) | 9/48 (18.8%) |
Unilateral infiltrates | 16/48 (33.3%) |
Microbiology | |
Sputum culture confirmation | 22/49 (44.9%) (+8 sputum culture ongoing) |
NAAT confirmation | 13/49 (26.5%) |
Sputum smear positive | 9/49 (18.4%) |
Not available | 5/49 (10.2%) |
Drug resistance | |
Resistant | 8/45 (17.8%) (4 MDR-TB) |
Sensitive | 37/45 (82.2%) |
Treatment outcome | |
Cured | 6/49 (12.2%) |
Completed | 1/49 (2.0%) |
On treatment | 37/49 (75.5%) |
Died# | 5/49 (10.2%) |
Lost to follow-up | 0 |
Failure | 0 |
COVID-19 | |
Symptoms | |
Asymptomatic | 5/48 (10.4%) |
Symptomatic | 43/48 (89.6%) |
Imaging | |
Typical (bilateral ground glass opacities) HRCT picture | 21/44 (47.7%) |
Treatment outcome | |
Resolved | 18/49 (36.7%) |
Still on treatment | 25/49 (51.0%) |
Died (at any date)# | 6/49 (12.3%) |
Abbreviations: SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TB: tuberculosis; BCG: Bacillus Calmette-Guérin; COPD: chronic obstructive pulmonary disease; a: ≥14 drinks per week in men or ≥7 drinks per week in women; b: current or ex-smoker; NAAT: Nuclear Acid Amplification Test; MDR-TB: multidrug-resistant tuberculosis.
#According to the criteria for cohort analysis of treatment results the patients died during anti-TB treatment are 5 but the total number of deaths is 6 as one patient with post-TB treatment sequelae died after being cured for TB.